These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27332721)

  • 1. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Halilbasic E; Fuchs C; Traussnigg S; Trauner M
    Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acid receptors as targets for drug development.
    Schaap FG; Trauner M; Jansen PL
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):55-67. PubMed ID: 23982684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid receptors and the kidney.
    Herman-Edelstein M; Weinstein T; Levi M
    Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
    Chiang JYL; Ferrell JM
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
    Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
    Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
    Sun L; Cai J; Gonzalez FJ
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile Acids and Portal Hypertension.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and challenges of selective Farnesoid X Receptor modulation.
    Massafra V; Pellicciari R; Gioiello A; van Mil SWC
    Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
    Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
    Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.
    Nolan JD; Johnston IM; Walters JR
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):49-56. PubMed ID: 23265149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5.
    Trammell SAJ; Svenningsen JS; Holst JJ; Gillum MP; Kuhre RE
    Molecules; 2020 May; 25(10):. PubMed ID: 32443832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.
    Portincasa P; Di Ciaula A; Garruti G; Vacca M; De Angelis M; Wang DQ
    Nutrients; 2020 Nov; 12(12):. PubMed ID: 33266235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile acid receptors in non-alcoholic fatty liver disease.
    Li Y; Jadhav K; Zhang Y
    Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic functions of bile acids mediated by the farnesoid X receptor.
    Stanimirov B; Stankov K; Mikov M
    Acta Gastroenterol Belg; 2012 Dec; 75(4):389-98. PubMed ID: 23402081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases.
    Stanimirov B; Stankov K; Mikov M
    Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):18-33. PubMed ID: 25655287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
    Piglionica M; Cariello M; Moschetta A
    Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.